Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about NeoGenomics, Inc.
NeoGenomics, Inc. News
NeoGenomics, Inc. Quantitative Score
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
NeoGenomics, Inc. Financials
Table Compare
Compare NEO metrics with: | |||
|---|---|---|---|
Earnings & Growth | NEO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NEO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NEO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NEO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
NeoGenomics, Inc. Income
NeoGenomics, Inc. Balance Sheet
NeoGenomics, Inc. Cash Flow
NeoGenomics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
NeoGenomics, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.4000 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2020-12-30 | 0.4 | Quarterly |
Historical Market Cap
Shares Outstanding
NeoGenomics, Inc. Executives
| Name | Role |
|---|---|
| Warren Stone | President & COO |
| Jeffrey S. Sherman | Chief Financial Officer |
| Alicia Olivo | Executive Vice President of Business Development, General Counsel & Corporate Secretary |
| Anthony Zook | Chief Executive Officer & Director |
| Elizabeth A. Floegel | Chief Digital & Information Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Warren Stone | President & COO | Male | 1973 | 1.14M |
| Jeffrey S. Sherman | Chief Financial Officer | Male | 1966 | 1.13M |
| Alicia Olivo | Executive Vice President of Business Development, General Counsel & Corporate Secretary | Female | 1984 | 958.25K |
| Anthony Zook | Chief Executive Officer & Director | Male | 1961 | 80.36K |
| Elizabeth A. Floegel | Chief Digital & Information Officer | Female | 1976 | 65K |
NeoGenomics, Inc. Insider Trades
| Date | 13 Jan |
| Name | Stone Warren |
| Role | Pres & Chief Operating Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 59382 |
| Date | 13 Jan |
| Name | Stone Warren |
| Role | Pres & Chief Operating Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 15127 |
| Date | 13 Jan |
| Name | Olivo Alicia C |
| Role | EVP, GC & Business Development |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 59382 |
| Date | 13 Jan |
| Name | Olivo Alicia C |
| Role | EVP, GC & Business Development |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 15145 |
| Date | 1 Jan |
| Name | Kenny John P. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 4171 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 13 Jan | Stone Warren | Pres & Chief Operating Officer | Acquired | M-Exempt | 59382 |
| 13 Jan | Stone Warren | Pres & Chief Operating Officer | Disposed | F-InKind | 15127 |
| 13 Jan | Olivo Alicia C | EVP, GC & Business Development | Acquired | M-Exempt | 59382 |
| 13 Jan | Olivo Alicia C | EVP, GC & Business Development | Disposed | F-InKind | 15145 |
| 1 Jan | Kenny John P. | Director | Acquired | A-Award | 4171 |